

First half of 2014:

Sartorius Stedim Biotech continues dynamic growth

in € million unless otherwise specified Unaudited figures	1 st half 2014	1 st half 2013	Growth in %	Growth in % const. fx
Order intake	338.4	311.5	8.7	10.7
Sales revenue	324.1	292.6	10.8	12.7
Europe ¹⁾	159.2	146.0	9.1	8.5
North America ¹⁾	90.8	73.1	24.2	28.6
Asia Pacific ¹⁾	64.1	60.1	6.7	12.1
Other Markets ¹⁾	10.0	13.4	-25.1	-25.1
EBITDA ²⁾³⁾	73.8	67.4	9.5	
EBITDA margin ²⁾³⁾ in %	22.8	23.0		
EBITA ²⁾³⁾	62.5	57.4	9.0	
EBITA margin ²⁾³⁾ in %	19.3	19.6		
Net profit ²⁾⁴⁾	40.7	38.0	7.1	
Earnings per share in € ²⁾⁴⁾	2.65	2.47	7.1	

¹⁾ According to customers' location ²⁾ Underlying = adjusted for extraordinary items

³⁾ Amortization refers only to amortization of intangible assets due to purchase price allocation (PPA) acc. to IFRS 3

⁴⁾ Underlying net profit after non-controlling interest and excluding amortization and fair value adjustments of hedging instruments

The Sartorius Stedim Biotech Group uses earnings before interest, taxes, depreciation and amortization (EBITDA) for measuring the profitability of the Group.

The key indicator "underlying EBITDA" corresponds to EBITDA adjusted for extraordinary items.

Double-digit top-line growth

In the first half of 2014, Sartorius Stedim Biotech, a leading supplier for the biopharmaceutical industry, continued on the growth track: Backed by recent acquisitions and significant organic growth with single-use products, order intake and sales revenue were up in double digits. All major regions contributed to the strong gains in sales, with North America in the lead.

Profit continues to rise

Despite continued headwinds from currency exchange rates, Sartorius Stedim Biotech again increased its earnings. Underlying EBITDA rose 9.5% to 73.8 million euros, and the corresponding margin was 22.8%. Extraordinary expenses accounted for 2.2 million euros. Underlying earnings per share were 2.65 euros, up from 2.47 euros in the first six months of 2013.

Key financial indicators at comfortable levels

The financial position of the Sartorius Stedim Biotech Group has remained strong and stable as reflected by an equity ratio of 54.2%, a gearing ratio of 0.3 and a ratio of net debt to underlying EBITDA of 0.9. Net debt at the end of the first half was 132.1 million euros.

Sartorius Stedim Biotech S.A.
 Z.I. Les Paluds
 Avenue de Jouques
 C.S. 91051
 13781 Aubagne - France
www.sartorius-stedim.com

Contact:
 Petra Kirchhoff
 Phone +49 (0)551.308.1686

Goettingen, July 22, 2014

Outlook for 2014 confirmed

Based on Sartorius Stedim Biotech's strong first-half performance, management confirmed and specified its full-year forecast for 2014. Sales growth in constant currencies is expected to reach the upper end of the 11% to 14% range, while the underlying EBITDA margin is forecasted to rise to approx. 23.5% in constant currencies. Furthermore, the Capex ratio is projected to be in the range of 6% to 8%.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

Conference call and webcast

Joachim Kreuzburg, CEO and Chairman of the Board of the Sartorius Stedim Biotech Group, will discuss the results with analysts and investors on Tuesday, July 22, 2014, at 3:30 p.m. Central European Time (CET), in a teleconference. You may dial into the teleconference starting at 3:20 p.m. CET at the following numbers:

Germany: +49(0)69 2222 10638

France: +33(0)1 76 77 22 32

UK: +44(0)20 3427 1933

USA: +1646 254 3376

The dial-in code is: 6666926

To view the webcast or presentation, log onto: www.sartorius-stedim.com

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions."

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,600 people, and in 2013 earned sales revenue of 588.4 million euros.

Contact

Petra Kirchhoff, Vice President of Corporate Communications
Sartorius Corporate Administration GmbH, 37070 Goettingen, Germany
Phone: +49(0)551.308.1686; Fax: +49(0)551.308.3410
E-mail: petra.kirchhoff@sartorius.com; www.sartorius-stedim.com